|
|
|
|
|
Diphenylpyraline
drug data and news
Diphenylpyraline drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Diphenylpyraline | ||
| Brand Names/Synonyms | AN 1041; Allergen; Belfene; Dafen; Dayfen; Diafen; Diphenylpyralamine; Diphenylpyraline; Diphenylpyraline Hydrochloride; Diphenylpyrilene; Hispril; Histryl; Histyn; Hystryl; Lyssipoll; Mepiben; Neargal; P 253 | ||
| Indication | For use in the treatment of allergic rhinitis, hay fever, and allergic skin disorders | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Diphenylpyraline is an antihistamine that prevents, but does not reverse, responses mediated by histamine alone. Diphenylpyraline antagonizes most of the pharmacological effects of histamine, including urticaria and pruritus. Also, diphenylpyraline may exhibit anticholinergic actions (as do most of the antihistamines) and may thus provide a drying effect on the nasal mucosa. | ||
| Mechanism Of Action | Antihistamines such as diphenylpyraline used in the treatment of allergy act by competing with histamine for H1-receptor sites on effector cells. This reduces the effects of histamine, leading to a temporary reduction of allergy symptoms. | ||
| Diphenylpyraline News (When available) |
| ||
| Dosage Forms | TABLET | ||
| Drug_Category | Antihistamines; ATC:R06AA07 | ||
| Absorption | Well absorbed after oral administration. | ||
| Interactions |
Interactions for Diphenylpyraline: This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines). | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 4-benzhydryloxy-1-methyl-piperidine | ||
| Chemical Formula | C19H23NO | ||
| Molecular Weight | 281.392 g/mol | ||
| Smiles String | CN1CCC(CC1)OC(C2=CC=CC=C2)C3=CC=CC=C3 | ||
| Melting Point | Not Available | ||
| Water Solubility | Not Available | ||
| State | Solid | ||
| LogP/Hphobicity | 4.325 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Hepatic | ||
| Half Life | Not Available | ||
| Protein Binding [%] | > 99% in human serum albumin | ||
| RxList Link | Not Available>RXlist | ||
| Sponsored links | |||
| Drug Reference | http://www.drugs.com/MMX/Diphenylpyraline.html | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00719 | ||
| CAS Registry Number | 147-20-6 | ||
| KEGG Compound ID | Not Available | ||
| PubChem ID | SID:301606 | ||
| PharmGKB ID | Not Available | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 777285 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |